Loading...

Geron Corporation

0IV3.LLSE
Healthcare
Medical - Pharmaceuticals
£1.48
£0.08(6.09%)

Geron Corporation (0IV3.L) Company Profile & Overview

Explore Geron Corporation’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Geron Corporation (0IV3.L) Company Profile & Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

SectorHealthcare
IndustryMedical - Pharmaceuticals
CEODawn Carter Bir

Contact Information

650 473 7700
919 East Hillsdale Boulevard, Foster City, CA, 94404

Company Facts

229 Employees
IPO DateJan 29, 2018
CountryUS
Actively Trading

Frequently Asked Questions

;